* Q1'21 revenue of KRW 260.8 billion increased 26% compared to Q1'20. * Q1'21 operating profit o...
INCHEON, South Korea, April 21, 2021 /PRNewswire/ -- Samsung Biologics, the world's leading contrac...
INCHEON, South Korea, March 18, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced a...
INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced an...
INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) reported its...
INCHEON, South Korea, Jan. 13, 2021 /PRNewswire/ -- Samsung Biologics (207940.KS) set forth its dyn...
INCHEON, South Korea, Dec. 16, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announcedJoh...
INCHEON, South Korea, Dec. 4, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced the...
INCHEON, South Korea, Nov. 18, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) officially b...
INDIANAPOLIS and INCHEON, South Korea, Nov. 17, 2020 /PRNewswire/ -- Samsung Biologics' partnership...
INCHEON, South Korea, Oct. 4, 2020 /PRNewswire/ -- Samsung Biologics' Virtual Exhibition Hall was r...
INCHEON, South Korea and SUZHOU, China, Nov. 1, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) ...
INCHEON, South Korea and SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- At a virtual ceremony today, ...
INCHEON, South Korea, Oct. 21, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) maintained s...
INCHEON, South Korea, Oct. 20, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into ...
INCHEON, South Korea, Oct. 19, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into ...
INCHEON, South Korea, Sept. 23, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and Kanaph Thera...
INCHEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and AstraZeneca ...
INCHEON, South Korea, Sept. 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into...
INCHEON, South Korea, Aug. 4, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today held an...